Serum markers for prediction of pulmonary radiation syndromes. Part I: Surfactant apoprotein.
Detection of a biochemical marker indicating radiation lung injury prior to the onset of clinical pathologic events could prove valuable in patient management. An increased level of alveolar surfactant is one of the earliest detectable changes following lung irradiation, starting within hours of irradiation and persisting a maximum of 2-6 weeks. However, because broncho-alveolar lavage is impracticable and endothelial cell damage due to radiation results in changes in permeability of vessel wall with leakage of alveolar proteins into serum, identification of serum markers was sought. A series of experiments in rabbits are described that clearly demonstrate serum surfactant apoprotein is an accurate marker and predictor for later lethal radiation pneumonitis. At 3-7 days after graded single doses to lung, surfactant was found in the serum paralleling the dose response for lethality. Control studies with a physiologic agent such as terbutaline release alveolar surfactant, but no serum surfactant was detected. Monitoring serum surfactant could direct preventive intervention prior to clinicopathologic manifestation of pulmonary radiation syndromes.
Dept. Radiation Oncology, University of Rochester Cancer Center, NY.
P
P
Rubin
S
S
McDonald
P
P
Maasilta
J N
JN
Finkelstein
D L
DL
Shapiro
D
D
Penney
P K
PK
Gregory
D000818:Animals; D001059:Apoproteins / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis; D005260:Female; D008168:Lung / Q000528:radiation effects*; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants / Q000097:blood*; D011817:Rabbits; D011833:Radiation Injuries, Experimental / Q000097:blood*
D001059:Apoproteins; D015415:Biomarkers; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; C046616:pulmonary surfactant apoprotein